Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis

ACG Case Rep J. 2022 Jun 24;9(6):e00788. doi: 10.14309/crj.0000000000000788. eCollection 2022 Jun.

Abstract

Vedolizumab is used in the treatment of inflammatory bowel disease and is generally well tolerated. We report a 20-year-old man who presented with right flank pain on a background of ulcerative colitis. He was on vedolizumab with his last dose 1 week before the onset of symptoms. Kidney function tests revealed a serum creatinine of 171 μmoL/L and a C-reactive protein of 74 mg/L. Kidney biopsy demonstrated focal acute interstitial nephritis. He was prescribed oral prednisolone and achieved complete recovery of renal function within 3 weeks. At the follow-up after 4 months, his renal function remains normal.

Publication types

  • Case Reports